Chances of FDA approval for Spectrum Pharma's lung cancer candidate poziotinib and Oncopeptides' Pepaxto for multiple myeloma have taken a dive, after the regulator's expert advisors voted
The European Commission has approved Oncopeptides' Pepaxti in combination with dexamethasone for multiple myeloma patients with so-called triple class refractory disease – in other words th
